ABBV

A September filing shows Rep. Pete Sessions sold Apple stock worth over $100,000. The sale was reported on September 22, 2026.

The 2026 second‑half healthcare dividend roundup notes that Johnson & Johnson outshines AbbVie. The comparison highlights J&J’s strong balance sheet and buyback activity.

AbbVie received EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. The approval expands AbbVie’s treatment options for pediatric arthritis.

AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis. The approval covers patients who did not respond to, or could not tolerate, standard disease-modifying drugs. It is the eleventh indication Rinvoq holds in Europe. The Commission also cleared […]

AbbVie’s Rinvoq has secured EU approval for juvenile idiopathic arthritis, broadening its market reach. Clinical data show sustained improvements in disease activity.

A congressman with $11.5 million in trades continues to sell stocks, with no purchases since 2024. The latest moves list the names of the stocks sold.

The ALPS Medical Breakthroughs ETF is highlighted as a good entry point into late‑stage biotech during its pullback. The fund’s holdings are seen as valuable for big pharma.

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.